We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-18.74%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$404M
AUM Growth
-$183M
Cap. Flow
-$944K
Cap. Flow %
-0.23%
Top 10 Hldgs %
67.69%
Holding
33
New
3
Increased
15
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$10.4M
2
ESPR
Esperion Therapeutics
ESPR
+$9.76M
3
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$7.53M
4
BPMC
Blueprint Medicines
BPMC
+$6.28M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$5.48M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$13.3M
2
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$12.4M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$11.6M
4
CTMX icon
CytomX Therapeutics
CTMX
+$37.6K
5
CALA
Calithera Biosciences, Inc
CALA
+$28.3K

Sector Composition

Rank Sector Weight
1 Healthcare 64.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
1
DELISTED
Blueprint Medicines
BPMC
$47.7M 11.79%
2,640,251
+361,792
+16% +$6.28M
CNCE
2
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$37.6M 9.31%
2,755,318
+523,304
+23% +$7.53M
CYTK icon
3
Cytokinetics
CYTK
$10.9B
$30.6M 7.57%
4,340,729
+1,420,101
+49% +$10.4M
FWP
4
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$24.5M 6.06%
205,898
– –
CASC
5
DELISTED
Cascadian Therapeutics, Inc.
CASC
$23.9M 5.91%
3,133,228
– –
CTIC
6
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$23.8M 5.89%
4,479,694
+100,133
+2% +$800K
ARRY
7
DELISTED
Array Biopharma Inc
ARRY
$23.2M 5.73%
7,850,211
+1,167,500
+17% +$3.5M
CCXI
8
DELISTED
ChemoCentryx, Inc.
CCXI
$20.4M 5.04%
8,182,052
+1,504,330
+23% +$5.48M
IRWD icon
9
Ironwood Pharmaceuticals
IRWD
$614M
$19.2M 4.75%
2,096,360
-1,409,194
-40% -$11.6M
VTAE
10
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$13.8M 3.43%
2,089,014
+27,689
+1% +$252K
OMED
11
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$13.5M 3.35%
1,339,336
+347,903
+35% +$4.08M
ARQL
12
DELISTED
Arqule Inc
ARQL
$12.6M 3.13%
7,893,324
+1,083,481
+16% +$1.9M
XENE icon
13
Xenon Pharmaceuticals
XENE
$6.2B
$12.4M 3.07%
1,775,572
+650,000
+58% +$4.67M
QLTI
14
DELISTED
QLT Inc
QLTI
$11.3M 2.81%
5,701,609
+337,224
+6% +$804K
ESPR
15
DELISTED
Esperion Therapeutics
ESPR
$10.3M 2.54%
+606,801
New +$9.76M
TBRA
16
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$10.3M 2.54%
1,253,401
– –
CPXX
17
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$8.82M 2.18%
+800,000
New +$2.62M
CTMX icon
18
CytomX Therapeutics
CTMX
$714M
$7.82M 1.93%
606,138
-2,710
-0.4% -$37.6K
ALPN
19
DELISTED
Alpine Immune Sciences Inc
ALPN
$6.45M 1.6%
386,686
+87,933
+29% +$1.76M
ONCT
20
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$5.76M 1.42%
8,223
+249
+3% +$216K
FLNA
21
Filana Therapeutics
FLNA
$46.4M
$4.79M 1.19%
307,130
+42,508
+16% +$550K
VIRX
22
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.6M 0.64%
22,920
+171
+0.8% +$25.9K
LOXO
23
DELISTED
Loxo Oncology, Inc
LOXO
$2.05M 0.51%
74,870
-636,197
-89% -$13.3M
GYRE icon
24
Gyre Therapeutics
GYRE
$648M
$1.63M 0.4%
8,631
– –
GBIM
25
DELISTED
GLOBEIMMUNE INC COM STK (DE)
GBIM
$1.35M 0.34%
657,653
– –
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2016 Portfolio in Review

As of Q1 2016, BVF Inc held 33 positions worth $404M, down 31% from $587M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

BVF Inc's Q1 2016 filing shows 3 new, 15 increased, 4 reduced and 1 closed positions. Its largest new stake was Esperion Therapeutics: 606,801 shares worth $10.3M. The largest sale was Loxo Oncology, Inc, an estimated $13.3M.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 65% a quarter earlier.

  • BVF Inc's largest Q1 2016 buy was Esperion Therapeutics: 606,801 shares worth $10.3M.
  • BVF Inc added most to Cytokinetics in Q1 2016, an estimated $10.4M increase.
  • BVF Inc's biggest Q1 2016 reduction was Loxo Oncology, Inc, cutting an estimated $13.3M.
  • BVF Inc fully exited Five Prime Therapeutics, Inc. in Q1 2016, selling an estimated $12.4M.
  • BVF Inc's ten largest holdings make up 68% of its $404M portfolio in Q1 2016.
  • BVF Inc opened 3 new positions and closed 1 in Q1 2016.
  • BVF Inc's portfolio value fell 31% quarter-over-quarter to $404M.

Based on BVF Inc's 13F filing for Q1 2016, filed 16 May 2016.